525 - USE OF NEOADJUVANT CHEMOTHERAPY AND DISSECTION OF THE POSITIVE SENTINEL LYMPH NODES IN THE TREATMENT OF BREAST CANCER ONLY ON STAGES T1 TO T2

Abstract

Objective: Breast cancer is the most common cancer that occurs in women. Its treatment is based on mastectomy, which
can be radical or quadrantectomy. Surgery is performed with axillary lymph node dissection (ALND) or sentinel lymph
node dissection (SLND), in addition to the prior or subsequent use of radiotherapy and chemotherapy. This article aims,
in this sense, to evaluate the displacement of surgery with positive sentinel in patients undergoing neoadjuvant chemotherapy (NAC) and radiotherapy compared to standard treatment of ALND in positive or expectant sentinel in patients
with negative lymph nodes associated with NAC. Methods: This is a retrospective study based on an analysis of medical records from the Hospital São Vicente de Paulo (HSVP) in Guarapuava, PR, from 2011 to 2020. Patients are selected
for breast cancer at an early stage, with maximum stage IIIA, quadrantectomy, NAC, and lymph node sentinel biopsy
based on the patent blue application being the inclusion criteria for all groups. Results: The results showed recurrence
in two patients in the control group (7%) and in one patient in the study group (17%), which resulted in posterior death.
Conclusion: Standard breast cancer patients, who are in intermediate stage, post menopause and positive lymph node in
biopsy, had a better treatment response when compared with other patients. Furthermore, in this study, young patients
had a worse response than the others. However, more studies with diversification and longer follow-up time are needed
to have more solid conclusions.